Press release

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients
· ABTL0812 is administered in combination with carboplatin and paclitaxel
· Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona)lead the study, which includes other centers in Spain and France
The Catalan biopharmaceutical company Ability Pharmaceuticals, SL announced today the initiation of its first Phase 2 Clinical Trial with its novel targeted anticancer agent ABTL0812 to evaluate its efficacy and safety in combination with paclitaxel and carboplatin in 80 patients with advanced or recurrent endometrial cancer or squamous lung cancer as first-line therapy. The study will be conducted in Spain and France with Dr. Ana Oaknin at Vall d’Hebron Institute of Oncology (VHIO, Barcelona) as principal investigator for endometrial cancer and Dr. Ernest Nadal at Institut Català d’Oncologia (ICO, Hospitalet-Barcelona) as principal investigator for lung cancer. Dr. Jordi Rodon (also from VHIO) is the coordinating investigator.
Dr. Carles Domènech, Chief Executive Officer and co-founder of AbilityPharma, said: “We are very happy to have reached this important development milestone. We face with enthusiasm taking to clinical proof of concept a new important product to treat cancer patients, especially as first line choice in squamous lung cancer and endometrial cancer, clear unmet medical needs”.
“ABTL0812 has shown to be an extremely safe compound in patients during the Phase 1b with initial clinical efficacy and high activity on biomarkers”, said Dr. José Alfón, Vice-President of Research and Development at AbilityPharma. “Additionally, the high efficacy and safety observed in combination in preclinical models make us expect good results in the phase 2 trial”.
Developed by Web4Bio